StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) in a report issued on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Aptevo Therapeutics Price Performance
Shares of Aptevo Therapeutics stock opened at $0.30 on Tuesday. The company has a 50-day moving average of $0.69 and a two-hundred day moving average of $3.68. Aptevo Therapeutics has a 12-month low of $0.28 and a 12-month high of $80.96.
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last released its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($9.95) earnings per share for the quarter, beating the consensus estimate of ($14.10) by $4.15. As a group, equities research analysts forecast that Aptevo Therapeutics will post -8.86 earnings per share for the current year.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Further Reading
- Five stocks we like better than Aptevo Therapeutics
- What is the Dow Jones Industrial Average (DJIA)?
- This Stock’s Price Shifts Into High Gear With Analyst Upgrades
- Stock Dividend Cuts Happen Are You Ready?
- AI Boosts Glass Tech Leader Stock: Shares Up 75% and More to Come
- Investing in Travel Stocks Benefits
- AI Partnership Boosts This Top Tech Stock: Ready for More Gains?
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
